Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Market Cap	12.57B
Revenue (ttm)	2.83B
Net Income (ttm)	434.18M
Shares Out	228.73M
EPS (ttm)	2.33
PE Ratio	12.02
Forward PE	10.57
Dividend	1.31 (4.68%)
Ex-Dividend Date	Sep 5, 2025

Volume	390,100
Average Volume	580,264
Open	28.02
Previous Close	28.00
Day's Range	27.74 - 28.46
52-Week Range	21.70 - 42.95
Beta	0.39
RSI	48.93
Earnings Date	Aug 23, 2025

About HKG:6826

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyaluronate gel, anti-adhesion, and burn wound related products. In addition, it provides injectors, scalpels, suture needles and other products. Further, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 2,156
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6826

Financial Performance

In 2024, HKG:6826's revenue was 2.68 billion, an increase of 1.70% compared to the previous year's 2.63 billion. Earnings were 420.45 million, an increase of 1.04%.

Financial numbers in CNY